Evidence map›Paper›PMID 41271572›Full record

ArticleACS biomaterials science & engineering2025

In Situ Development of Quercetin-Enhanced Layered Double Hydroxides for Targeted Osteosarcoma Therapy.

Panagiota Zygouri, Grigorios Tsiodoulos, Marilena Lianou, Antrea-Maria Athinodorou, Eirini Papanikolaou, Yannis V Simos, Konstantinos Spyrou, Mohammed Subrati, Angela S Kaloudi, Konstantinos Tsamis and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Panagiota ZygouriDepartment of Materials Science and Engineering, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-7137-6633
Grigorios TsiodoulosDepartment of Maxillofacial, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Marilena LianouDepartment of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Antrea-Maria AthinodorouDepartment of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Eirini PapanikolaouNanomedicine and Nanobiotechnology Research Group, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-1554-2430
Yannis V SimosNanomedicine and Nanobiotechnology Research Group, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0003-1764-8906
Konstantinos SpyrouDepartment of Materials Science and Engineering, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-2032-8439
Mohammed SubratiInstitute of Nanoscience and Nanotechnology, NCSR "Demokritos", Aghia Paraskevi, 15310 Attikis, Greece.ORCID 0000-0002-9349-7073
Angela S KaloudiDepartment of Materials Science and Engineering, University of Ioannina, 45110 Ioannina, Greece.ORCID 0009-0006-4052-0002
Konstantinos TsamisNanomedicine and Nanobiotechnology Research Group, University of Ioannina, 45110 Ioannina, Greece.
Lampros LakkasNanomedicine and Nanobiotechnology Research Group, University of Ioannina, 45110 Ioannina, Greece.
Zili SideratouInstitute of Nanoscience and Nanotechnology, NCSR "Demokritos", Aghia Paraskevi, 15310 Attikis, Greece.
Fotios K KatsarosInstitute of Nanoscience and Nanotechnology, NCSR "Demokritos", Aghia Paraskevi, 15310 Attikis, Greece.
Dimitrios PeschosNanomedicine and Nanobiotechnology Research Group, University of Ioannina, 45110 Ioannina, Greece.
Vasileios RagosDepartment of Maxillofacial, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Dimitrios P GournisSchool of Chemical and Environmental Engineering, Technical University of Crete (TUC), GR-73100 Chania, Crete, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigated the structural, thermal, and cytotoxic properties of Mg-Al layered double hydroxides (LDHs) intercalated with quercetin. Fourier transform infrared (FTIR) and Raman spectroscopy confirmed the successful incorporation of quercetin into the LDH structure, while X-ray diffraction (XRD) showed an increased interlayer spacing due to quercetin intercalation. Thermogravimetric analysis (TGA) demonstrated greater thermal degradation in quercetin-intercalated LDHs compared to nitrate-intercalated LDHs, suggesting a higher quercetin content in the material. Atomic force microscopy (AFM) indicated morphological changes with quercetin, particularly larger surface clusters at room temperature. Cytotoxicity assays revealed that quercetin-intercalated LDHs exhibited a dose- and time-dependent reduction in cell viability, which was more pronounced at higher concentrations and longer exposure times. Quercetin alone had a stronger cytotoxic effect on NIH/3T3 cells compared with Saos-2 cells. Additionally, reactive oxygen species (ROS) assays showed distinct effects of quercetin on both cell lines. These findings highlight the potential of quercetin-LDH hybrids for biomedical applications, particularly for targeted drug delivery.

Indexed as

Antineoplastic AgentsHydroxidesOsteosarcomaQuercetinAnimalsCell Line, TumorCell SurvivalHumansMiceNIH 3T3 CellsReactive Oxygen SpeciesAntineoplastic AgentsHydroxidesQuercetinReactive Oxygen Speciescancercytotoxicityintercalationlayered double hydroxidesquercetin

Identifiers

PMID41271572
PMCPMC12690506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.